Integrated Shield riders: Fresh focus on cancer drug cover, brace for premium hikes
IP riders now have additional cancer drug benefits far more than the base plans, raising the question of whether current premiums are sustainable
RIDERS to supplement private Integrated Shield Plans (IPs) are set to take on new significance for policyholders, particularly if you are concerned about the extent of cancer drug coverage.
The big question is – are today’s rider premiums sustainable given the riders’ enlarged role in outpatient cancer cover?
Insurers in the IP scheme recently rolled out their base IP plans and riders, with reference to the caps for cancer drug coverage, in line with the cancer drug list (CDL) issued by the health ministry last year.
TRENDING NOW
Two-thirds of Sentosa Cove resales in the red, with average loss topping S$1 million since 2023
Singapore at 61: How we can ensure opportunity, security and ownership for the next generation
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
How BYD disrupted Singapore’s car market – and why the strategy is turning on itself